SU1433390A3 - Способ получени антибактериальной соли щелочного металла 7 @ -дифторметил-тиоацефамидо-7 @ -метокси-3-[1-(2-гидроксиалкил)-1Н-тетразол-5-ил]тиометил-1-детиа-1-окса-3-цефем-4-карбоновой кислоты - Google Patents
Способ получени антибактериальной соли щелочного металла 7 @ -дифторметил-тиоацефамидо-7 @ -метокси-3-[1-(2-гидроксиалкил)-1Н-тетразол-5-ил]тиометил-1-детиа-1-окса-3-цефем-4-карбоновой кислоты Download PDFInfo
- Publication number
- SU1433390A3 SU1433390A3 SU3786902A SU3786902A SU1433390A3 SU 1433390 A3 SU1433390 A3 SU 1433390A3 SU 3786902 A SU3786902 A SU 3786902A SU 3786902 A SU3786902 A SU 3786902A SU 1433390 A3 SU1433390 A3 SU 1433390A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- alkali metal
- carboxylic acid
- thiomethyl
- methoxy
- cephem
- Prior art date
Links
- 229910052783 alkali metal Inorganic materials 0.000 title claims abstract description 5
- 238000000034 method Methods 0.000 title claims description 4
- 150000001340 alkali metals Chemical class 0.000 title claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 title claims description 3
- 150000003839 salts Chemical class 0.000 title claims description 3
- 239000003381 stabilizer Substances 0.000 claims abstract description 5
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229930091371 Fructose Natural products 0.000 claims abstract description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 3
- 239000005715 Fructose Substances 0.000 claims abstract description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims abstract description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims abstract description 3
- 239000008103 glucose Substances 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 239000012153 distilled water Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 3
- IKWLIQXIPRUIDU-ZCFIWIBFSA-N (6r)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound OC(=O)C1=CCS[C@@H]2CC(=O)N12 IKWLIQXIPRUIDU-ZCFIWIBFSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- -1 alkali metal salt Chemical class 0.000 abstract 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 abstract 1
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 1
- 239000011707 mineral Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 5
- 239000011734 sodium Substances 0.000 description 4
- 238000000859 sublimation Methods 0.000 description 4
- 230000008022 sublimation Effects 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cephalosporin Compounds (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58153938A JPS6045514A (ja) | 1983-08-22 | 1983-08-22 | 安定な抗菌性凍結乾燥製剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1433390A3 true SU1433390A3 (ru) | 1988-10-23 |
Family
ID=15573358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU3786902A SU1433390A3 (ru) | 1983-08-22 | 1984-08-21 | Способ получени антибактериальной соли щелочного металла 7 @ -дифторметил-тиоацефамидо-7 @ -метокси-3-[1-(2-гидроксиалкил)-1Н-тетразол-5-ил]тиометил-1-детиа-1-окса-3-цефем-4-карбоновой кислоты |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US4616083A (enExample) |
| EP (1) | EP0134568B1 (enExample) |
| JP (1) | JPS6045514A (enExample) |
| KR (1) | KR910004575B1 (enExample) |
| AR (1) | AR242390A1 (enExample) |
| AT (1) | ATE38774T1 (enExample) |
| CA (1) | CA1231896A (enExample) |
| DE (2) | DE3475268D1 (enExample) |
| DK (1) | DK163032C (enExample) |
| ES (1) | ES8505815A1 (enExample) |
| FI (1) | FI83476C (enExample) |
| GB (1) | GB2145333B (enExample) |
| GR (1) | GR80147B (enExample) |
| IE (1) | IE57587B1 (enExample) |
| IL (1) | IL72731A (enExample) |
| NO (1) | NO165223C (enExample) |
| NZ (1) | NZ209111A (enExample) |
| PT (1) | PT79093B (enExample) |
| SU (1) | SU1433390A3 (enExample) |
| ZA (1) | ZA846104B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61130223A (ja) * | 1984-11-28 | 1986-06-18 | Shionogi & Co Ltd | 抗菌性凍結乾燥製剤 |
| US4808617A (en) * | 1985-12-18 | 1989-02-28 | Bristol-Myers Company | Lyophilized or precipitated cephalosporin zwitterion and salt combination |
| DE3801179A1 (de) * | 1988-01-18 | 1989-07-27 | Hoechst Ag | Stabilisierung von cephalosporinderivaten durch trocknung mit einem stabilisator sowie stabile zubereitungsformen mit cephalosporinderivaten |
| KR0154343B1 (ko) * | 1990-11-06 | 1998-11-16 | 아만 히데아키 | 동결 건조 제제 및 이의 제조방법 |
| US7378408B2 (en) * | 2001-11-30 | 2008-05-27 | Pfizer Inc. | Methods of treatment and formulations of cephalosporin |
| WO2004000323A1 (ja) * | 2002-06-21 | 2003-12-31 | Shionogi & Co., Ltd. | セフェム化合物の注射用医薬組成物 |
| KR101314500B1 (ko) * | 2012-12-28 | 2013-10-07 | 제일약품주식회사 | 안정성이 개선된 옥사세펨 제제 및 그 제조방법 |
| US9320740B2 (en) | 2013-03-15 | 2016-04-26 | Merck Sharp & Dohme Corp. | Ceftolozane-tazobactam pharmaceutical compositions |
| EP2893929B1 (en) | 2013-03-15 | 2025-04-16 | Merck Sharp & Dohme LLC | Ceftolozane antibiotic compositions |
| US9872906B2 (en) | 2013-03-15 | 2018-01-23 | Merck Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
| US10376496B2 (en) | 2013-09-09 | 2019-08-13 | Merck, Sharp & Dohme Corp. | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
| US8906898B1 (en) | 2013-09-27 | 2014-12-09 | Calixa Therapeutics, Inc. | Solid forms of ceftolozane |
| CN106687116B (zh) * | 2014-09-04 | 2020-07-24 | 盐野义制药株式会社 | 含有具有儿茶酚基的头孢菌素类的制剂 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA919593A (en) * | 1969-03-31 | 1973-01-23 | Nippon Kayaku Kabushiki Kaisha | Process for manufacturing a preparation containing finely divided chloramphenicol palmitate |
| US3993753A (en) * | 1974-08-26 | 1976-11-23 | American Home Products Corporation | Anhydrous ampicillin stabilization and resultant compositions |
| US4180571A (en) * | 1976-03-25 | 1979-12-25 | Shionogi & Co., Ltd. | Arylmalonamido-1-oxadethiacephalosporins |
| JPS5711909A (en) * | 1980-06-23 | 1982-01-21 | Shionogi & Co Ltd | Stable freeze-dried preparation of beta-lactam |
| JPS5762284A (en) * | 1980-10-01 | 1982-04-15 | Sumitomo Chem Co Ltd | Stabilizing method |
| JPS59139385A (ja) * | 1982-12-23 | 1984-08-10 | Shionogi & Co Ltd | フルオロメチルチオオキサセフアロスポリン |
-
1983
- 1983-08-22 JP JP58153938A patent/JPS6045514A/ja active Granted
-
1984
- 1984-08-03 CA CA000460356A patent/CA1231896A/en not_active Expired
- 1984-08-03 ES ES535654A patent/ES8505815A1/es not_active Expired
- 1984-08-03 NZ NZ209111A patent/NZ209111A/en unknown
- 1984-08-07 ZA ZA846104A patent/ZA846104B/xx unknown
- 1984-08-09 GB GB08420296A patent/GB2145333B/en not_active Expired
- 1984-08-10 IE IE2072/84A patent/IE57587B1/en not_active IP Right Cessation
- 1984-08-16 PT PT79093A patent/PT79093B/pt not_active IP Right Cessation
- 1984-08-17 US US06/641,821 patent/US4616083A/en not_active Expired - Lifetime
- 1984-08-17 FI FI843261A patent/FI83476C/fi not_active IP Right Cessation
- 1984-08-18 KR KR1019840004996A patent/KR910004575B1/ko not_active Expired
- 1984-08-20 GR GR80147A patent/GR80147B/el unknown
- 1984-08-20 NO NO843313A patent/NO165223C/no unknown
- 1984-08-21 EP EP84109944A patent/EP0134568B1/en not_active Expired
- 1984-08-21 SU SU3786902A patent/SU1433390A3/ru active
- 1984-08-21 DE DE8484109944T patent/DE3475268D1/de not_active Expired
- 1984-08-21 DK DK399684A patent/DK163032C/da not_active IP Right Cessation
- 1984-08-21 IL IL72731A patent/IL72731A/xx not_active IP Right Cessation
- 1984-08-21 AR AR84297646A patent/AR242390A1/es active
- 1984-08-21 AT AT84109944T patent/ATE38774T1/de not_active IP Right Cessation
- 1984-08-21 DE DE198484109944T patent/DE134568T1/de active Pending
Non-Patent Citations (1)
| Title |
|---|
| Патент JP № 57-11909, кл. А 61 К 9/00, 1982. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU1433390A3 (ru) | Способ получени антибактериальной соли щелочного металла 7 @ -дифторметил-тиоацефамидо-7 @ -метокси-3-[1-(2-гидроксиалкил)-1Н-тетразол-5-ил]тиометил-1-детиа-1-окса-3-цефем-4-карбоновой кислоты | |
| JP5371755B2 (ja) | β−ラクタム系抗生物質と緩衝成分を含有する抗生物質複方 | |
| JP2010501493A (ja) | アミノグリコシド系抗生物質を含有する抗生物質複方 | |
| AU758857B2 (en) | Pharmaceutical compositions for freeze drying | |
| HU199686B (en) | Process for producing combination of liophylized or precipitated diion forme and salt of cephalosporin | |
| US3928592A (en) | Antibiotic pharmaceutical compositions | |
| US5095011A (en) | Lyophilized cefepime dihydrochloride for parenteral use | |
| ES2048263T3 (es) | Composicion liofilizada de mdm y metodo para su fabricacion. | |
| CA1308358C (en) | Antibacterial lyophilized preparation | |
| US6160165A (en) | Method for preparation of disodium pamidronate | |
| JPH0522688B2 (enExample) | ||
| RU2080856C1 (ru) | Способ получения инъекционной формы препарата атф | |
| GB2072675A (en) | Cephapirin salts | |
| JPH0443074B2 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REG | Reference to a code of a succession state |
Ref country code: RU Ref legal event code: MM4A Effective date: 20030822 |